IDEXX Laboratories, Inc. (NASDAQ:IDXX) Stake Lessened by Eagle Asset Management Inc.

Eagle Asset Management Inc. trimmed its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 56.1% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 119,965 shares of the company's stock after selling 153,314 shares during the quarter. Eagle Asset Management Inc. owned approximately 0.15% of IDEXX Laboratories worth $60,609,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Eads & Heald Wealth Management lifted its holdings in IDEXX Laboratories by 0.8% in the 2nd quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company's stock valued at $1,309,000 after purchasing an additional 22 shares in the last quarter. LRI Investments LLC raised its position in shares of IDEXX Laboratories by 21.7% in the second quarter. LRI Investments LLC now owns 129 shares of the company's stock valued at $63,000 after buying an additional 23 shares during the last quarter. Sovereign Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 5.1% during the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company's stock valued at $237,000 after buying an additional 23 shares during the period. Mather Group LLC. boosted its position in IDEXX Laboratories by 3.9% during the third quarter. Mather Group LLC. now owns 617 shares of the company's stock worth $312,000 after acquiring an additional 23 shares during the last quarter. Finally, Angeles Wealth Management LLC grew its stake in IDEXX Laboratories by 2.4% in the 3rd quarter. Angeles Wealth Management LLC now owns 1,078 shares of the company's stock worth $545,000 after acquiring an additional 25 shares during the period. 87.84% of the stock is currently owned by hedge funds and other institutional investors.

IDEXX Laboratories Trading Up 0.1 %

Shares of IDEXX Laboratories stock traded up $0.56 during trading hours on Friday, hitting $419.11. The company's stock had a trading volume of 239,047 shares, compared to its average volume of 502,250. IDEXX Laboratories, Inc. has a 1-year low of $398.50 and a 1-year high of $583.39. The company has a market capitalization of $34.32 billion, a PE ratio of 40.44, a P/E/G ratio of 3.63 and a beta of 1.36. The company has a quick ratio of 1.03, a current ratio of 1.42 and a debt-to-equity ratio of 0.32. The business has a fifty day moving average of $462.53 and a 200 day moving average of $481.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The company reported $2.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The company had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter last year, the company earned $2.53 earnings per share. IDEXX Laboratories's revenue for the quarter was up 6.6% on a year-over-year basis. As a group, equities analysts forecast that IDEXX Laboratories, Inc. will post 10.43 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on IDXX. Piper Sandler restated a "neutral" rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Stifel Nicolaus lowered their price target on IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating for the company in a report on Thursday, October 10th. Barclays cut their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating on the stock in a report on Monday, November 4th. JPMorgan Chase & Co. lowered their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a report on Friday, October 11th. Finally, BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They set a "buy" rating and a $580.00 price target on the stock. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, IDEXX Laboratories currently has an average rating of "Moderate Buy" and a consensus target price of $552.38.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.